1
|
Kumari L, Choudhari Y, Patel P, Gupta GD, Singh D, Rosenholm JM, Bansal KK, Kurmi BD. Advancement in Solubilization Approaches: A Step towards Bioavailability Enhancement of Poorly Soluble Drugs. Life (Basel) 2023; 13:life13051099. [PMID: 37240744 DOI: 10.3390/life13051099] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Revised: 04/20/2023] [Accepted: 04/25/2023] [Indexed: 05/28/2023] Open
Abstract
A drug's aqueous solubility is defined as the ability to dissolve in a particular solvent, and it is currently a major hurdle in bringing new drug molecules to the market. According to some estimates, up to 40% of commercialized products and 70-90% of drug candidates in the development stage are poorly soluble, which results in low bioavailability, diminished therapeutic effects, and dosage escalation. Because of this, solubility must be taken into consideration when developing and fabricating pharmaceutical products. To date, a number of approaches have been investigated to address the problem of poor solubility. This review article attempts to summarize several conventional methods utilized to increase the solubility of poorly soluble drugs. These methods include the principles of physical and chemical approaches such as particle size reduction, solid dispersion, supercritical fluid technology, cryogenic technology, inclusion complex formation techniques, and floating granules. It includes structural modification (i.e., prodrug, salt formation, co-crystallization, use of co-solvents, hydrotrophy, polymorphs, amorphous solid dispersions, and pH variation). Various nanotechnological approaches such as liposomes, nanoparticles, dendrimers, micelles, metal organic frameworks, nanogels, nanoemulsions, nanosuspension, carbon nanotubes, and so forth have also been widely investigated for solubility enhancement. All these approaches have brought forward the enhancement of the bioavailability of orally administered drugs by improving the solubility of poorly water-soluble drugs. However, the solubility issues have not been completely resolved, owing to several challenges associated with current approaches, such as reproducibility in large scale production. Considering that there is no universal approach for solving solubility issues, more research is needed to simplify the existing technologies, which could increase the number of commercially available products employing these techniques.
Collapse
Affiliation(s)
- Lakshmi Kumari
- Department of Pharmaceutics, ISF College of Pharmacy, GT Road, Moga 142001, Punjab, India
| | - Yash Choudhari
- Department of Pharmaceutics, ISF College of Pharmacy, GT Road, Moga 142001, Punjab, India
| | - Preeti Patel
- Department of Pharmaceutical Chemistry, ISF College of Pharmacy, GT Road, Moga 142001, Punjab, India
| | - Ghanshyam Das Gupta
- Department of Pharmaceutics, ISF College of Pharmacy, GT Road, Moga 142001, Punjab, India
| | - Dilpreet Singh
- Department of Pharmaceutics, ISF College of Pharmacy, GT Road, Moga 142001, Punjab, India
| | - Jessica M Rosenholm
- Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, 20520 Turku, Finland
| | - Kuldeep Kumar Bansal
- Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, 20520 Turku, Finland
| | - Balak Das Kurmi
- Department of Pharmaceutics, ISF College of Pharmacy, GT Road, Moga 142001, Punjab, India
| |
Collapse
|
2
|
Vanderschaeghe H, Houlleberghs M, Verheyden L, Dom D, Chandran CV, Radhakrishnan S, Martens JA, Breynaert E. Absolute Quantification of Residual Solvent in Mesoporous Silica Drug Formulations Using Magic-Angle Spinning NMR Spectroscopy. Anal Chem 2022; 95:1880-1887. [PMID: 36579853 DOI: 10.1021/acs.analchem.2c03646] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Porous silica is used as a drug delivery agent to improve the bioavailability of sparsely soluble compounds. In this approach, the active pharmaceutical ingredient (API) is commonly loaded into the porous silica by incipient wetness impregnation using organic solvents. Subsequent solvent elimination is critical as the residual solvent concentration cannot exceed threshold values set by health and safety regulations (e.g., EMA/CHMP/ICH/82260/2006). For dichloromethane and methanol, for example, residual concentrations must be below 600 and 3000 ppm, respectively. Today, EU and USA Pharmacopoeias recommend tedious procedures for residual solvent quantification, requiring extraction of the solvent and subsequent quantification using capillary gas chromatography with static headspace sampling (sHS-GC). This work presents a new method based on the combination of standard addition and absolute quantification using magic-angle spinning nuclear magnetic resonance spectroscopy (MAS qNMR). The methodology was originally developed for absolute quantification of water in zeolites and has now been validated for quantification of residual solvent in drug formations using mesoporous silica loaded with ibuprofen dissolved in DCM and MeOH as test samples. Interestingly, formulations prepared using as-received or predried mesoporous silica contained 5465 versus 484.9 ppm DCM, respectively. This implies that the initial water content of the silica carrier can impact the residual solvent concentration in drug-loaded materials. This observation could provide new options to minimize the occurrence of these undesired solvents in the final formulation.
Collapse
Affiliation(s)
- Hannah Vanderschaeghe
- Center for Surface Chemistry and Catalysis (COK-kat), KU Leuven, Celestijnenlaan 200F, Box 2461, 3001Heverlee, Belgium
| | - Maarten Houlleberghs
- Center for Surface Chemistry and Catalysis (COK-kat), KU Leuven, Celestijnenlaan 200F, Box 2461, 3001Heverlee, Belgium
| | - Loes Verheyden
- Center for Surface Chemistry and Catalysis (COK-kat), KU Leuven, Celestijnenlaan 200F, Box 2461, 3001Heverlee, Belgium
| | - Dirk Dom
- Center for Surface Chemistry and Catalysis (COK-kat), KU Leuven, Celestijnenlaan 200F, Box 2461, 3001Heverlee, Belgium
- NMR/X-ray platform for Convergence Research (NMRCoRe), KU Leuven, Celestijnenlaan 200F, Box 2461, 3001Heverlee, Belgium
| | - C Vinod Chandran
- Center for Surface Chemistry and Catalysis (COK-kat), KU Leuven, Celestijnenlaan 200F, Box 2461, 3001Heverlee, Belgium
- NMR/X-ray platform for Convergence Research (NMRCoRe), KU Leuven, Celestijnenlaan 200F, Box 2461, 3001Heverlee, Belgium
| | - Sambhu Radhakrishnan
- Center for Surface Chemistry and Catalysis (COK-kat), KU Leuven, Celestijnenlaan 200F, Box 2461, 3001Heverlee, Belgium
- NMR/X-ray platform for Convergence Research (NMRCoRe), KU Leuven, Celestijnenlaan 200F, Box 2461, 3001Heverlee, Belgium
| | - Johan A Martens
- Center for Surface Chemistry and Catalysis (COK-kat), KU Leuven, Celestijnenlaan 200F, Box 2461, 3001Heverlee, Belgium
| | - Eric Breynaert
- Center for Surface Chemistry and Catalysis (COK-kat), KU Leuven, Celestijnenlaan 200F, Box 2461, 3001Heverlee, Belgium
- NMR/X-ray platform for Convergence Research (NMRCoRe), KU Leuven, Celestijnenlaan 200F, Box 2461, 3001Heverlee, Belgium
| |
Collapse
|
3
|
Pulinthanathu Sree S, Breynaert E, Kirschhock CEA, Martens JA. Hierarchical COK-X Materials for Applications in Catalysis and Adsorptive Separation and Controlled Release. FRONTIERS IN CHEMICAL ENGINEERING 2022. [DOI: 10.3389/fceng.2022.810443] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Over the years, COK has developed a family of silicate materials and metal–organic framework hybrids with hierarchical porosity and functionality, coined zeogrids, zeotiles, and COK-x (stemming from the Flemish name of the laboratory “Centrum voor Oppervlaktechemie en Katalyse”). Several of these materials have unique features relevant to heterogeneous catalysis, molecular separation, and controlled release and found applications in the field of green chemistry, environmental protection, and pharmaceutical formulation. Discovery of a new material typically occurs by serendipity, but the research was always guided by hypothesis. This review provides insight in the process of tuning initial research hypotheses to match material properties to specific applications. This review describes the synthesis, structure, properties, and applications of 12 different materials. Some have simple synthesis protocols, facilitating upscaling and reproduction and rendering them attractive also in this respect.
Collapse
|
4
|
Superiority of Mesoporous Silica-Based Amorphous Formulations over Spray-Dried Solid Dispersions. Pharmaceutics 2022; 14:pharmaceutics14020428. [PMID: 35214159 PMCID: PMC8878785 DOI: 10.3390/pharmaceutics14020428] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2022] [Accepted: 02/13/2022] [Indexed: 12/04/2022] Open
Abstract
The aim of this study was to compare the performance of two amorphous formulation strategies: mesoporous silica via solvent impregnation, and solid dispersions by spray drying. Poorly soluble fenofibrate was chosen as the model drug compound. A total of 30% Fenofibrate-loaded mesoporous silica and spray-dried solid dispersions (SDD) were prepared for head-to-head comparisons, including accelerated stability, manufacturability, and in vitro biorelevant dissolution. In the accelerated stability study under 40 °C/75% RH in open dish, mesoporous silica was able to maintain amorphous fenofibrate for up to 3 months based on solid-state characterizations by PXRD and DSC. This result was superior compared to SDD, as recrystallization was observed within 2 weeks. Under the same drug load, fenofibrate-loaded mesoporous silica showed much better flowability than fenofibrate-loaded SDD, which is beneficial for powder handling of the intermediate product during the downstream process. The in vitro 2-stage dissolution results indicated a well-controlled release of fenofibrate from mesoporous silica in the biorelevant media, rather than a burst release followed by fast precipitation due to the recrystallization in the early simulated gastric phase for SDD. The present study demonstrates that mesoporous silica is a promising formulation platform alternative to prevailing spray-dried solid dispersions for oral drug product development.
Collapse
|
5
|
Maghsoodi M, Shahi F. Combined Use of Polymers and Porous Materials to Enhance Cinnarizine Dissolution. PHARMACEUTICAL SCIENCES 2019. [DOI: 10.15171/ps.2019.44] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Background: Loading of poorly water-soluble drugs on the porous materials has attracted great interest as an effective approach for enhancement of dissolution rate of drugs. The Aerosil (Ae) with porous structure is expected to facilitate the dissolution of drugs which is generally associated with precipitation. Thus, the purpose of this investigation was thus to develop a formulation which combines a precipitation inhibitor and a poorly soluble drug loaded Ae. Methods: A poorly water-soluble drug, Cinnarizine (CNZ) was used as a model, and Eudragit L100 (Eu) was used as a precipitation inhibitor. Formulations were produced by solvent evaporation and characterized by FT-IR and differential scanning calorimetry (DSC). Dissolution experiments were carried out in phosphate buffer (pH 6.8) under non-sink conditions. Results: DSC thermograms revealed that no crystalline structure of CNZ was present in CNZ-loaded Ae formulations and no long-range order was arranged upon loading of CNZ into Ae. In dissolution test, the CNZ-loaded Ae physically blended with Eu achieved a remarkedly higher CNZ concentration over the plain CNZ and over the CNZ-Eu co-loaded Ae. The dissolution rate of CNZ from the CNZ-loaded Ae was enhanced with increasing Ae amount and the dissolution was maximum when the ratio of CNZ: Ae was 1:10 CNZ: Ae. In addition, the precipitation inhibition was increased when the amount of Eu was high. Conclusion: The results of this work revealed that the dissolution behaviour of CNZ-loaded Ae is enhanced by physically blending of Eu as a suitable precipitation inhibitor.
Collapse
Affiliation(s)
- Maryam Maghsoodi
- Drug Applied Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Fatemeh Shahi
- Drug Applied Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
| |
Collapse
|
6
|
Flynn J, Mallen S, Durack E, O'Connor PM, Hudson SP. Mesoporous matrices for the delivery of the broad spectrum bacteriocin, nisin A. J Colloid Interface Sci 2019; 537:396-406. [DOI: 10.1016/j.jcis.2018.11.037] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2018] [Revised: 11/04/2018] [Accepted: 11/10/2018] [Indexed: 12/31/2022]
|
7
|
High dispersed phyto-phospholipid complex/TPGS 1000 with mesoporous silica to enhance oral bioavailability of tanshinol. Colloids Surf B Biointerfaces 2018; 170:187-193. [DOI: 10.1016/j.colsurfb.2018.06.013] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2018] [Revised: 05/10/2018] [Accepted: 06/08/2018] [Indexed: 12/18/2022]
|
8
|
Ditzinger F, Price DJ, Ilie AR, Köhl NJ, Jankovic S, Tsakiridou G, Aleandri S, Kalantzi L, Holm R, Nair A, Saal C, Griffin B, Kuentz M. Lipophilicity and hydrophobicity considerations in bio-enabling oral formulations approaches – a PEARRL review. J Pharm Pharmacol 2018; 71:464-482. [DOI: 10.1111/jphp.12984] [Citation(s) in RCA: 49] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2018] [Accepted: 06/27/2018] [Indexed: 11/30/2022]
Abstract
Abstract
Objectives
This review highlights aspects of drug hydrophobicity and lipophilicity as determinants of different oral formulation approaches with specific focus on enabling formulation technologies. An overview is provided on appropriate formulation selection by focussing on the physicochemical properties of the drug.
Key findings
Crystal lattice energy and the octanol–water partitioning behaviour of a poorly soluble drug are conventionally viewed as characteristics of hydrophobicity and lipophilicity, which matter particularly for any dissolution process during manufacturing and regarding drug release in the gastrointestinal tract. Different oral formulation strategies are discussed in the present review, including lipid-based delivery, amorphous solid dispersions, mesoporous silica, nanosuspensions and cyclodextrin formulations.
Summary
Current literature suggests that selection of formulation approaches in pharmaceutics is still highly dependent on the availability of technological expertise in a company or research group. Encouraging is that, recent advancements point to more structured and scientifically based development approaches. More research is still needed to better link physicochemical drug properties to pharmaceutical formulation design.
Collapse
Affiliation(s)
- Felix Ditzinger
- Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
- Institute of Pharma Technology, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland
| | - Daniel J Price
- Analytics Healthcare, Merck KGaA, Darmstadt, Germany
- Goethe University, Frankfurt, Germany
| | - Alexandra-Roxana Ilie
- School of Pharmacy, University College Cork, Cork, Ireland
- Drug Product Development, Janssen Research and Development, Johnson and Johnson, Beerse, Belgium
| | - Niklas J Köhl
- School of Pharmacy, University College Cork, Cork, Ireland
| | - Sandra Jankovic
- Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
- Institute of Pharma Technology, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland
| | - Georgia Tsakiridou
- Product Design & Evaluation, Pharmathen SA, Athens, Greece
- Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece
| | - Simone Aleandri
- Institute of Pharma Technology, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland
| | - Lida Kalantzi
- Product Design & Evaluation, Pharmathen SA, Athens, Greece
| | - René Holm
- Drug Product Development, Janssen Research and Development, Johnson and Johnson, Beerse, Belgium
| | - Anita Nair
- Analytics Healthcare, Merck KGaA, Darmstadt, Germany
| | | | | | - Martin Kuentz
- Institute of Pharma Technology, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland
| |
Collapse
|
9
|
Kevadiya BD, Barvaliya M, Zhang L, Anovadiya A, Brahmbhatt H, Paul P, Tripathi C. Fenofibrate Nanocrystals Embedded in Oral Strip-Films for Bioavailability Enhancement. Bioengineering (Basel) 2018; 5:bioengineering5010016. [PMID: 29438297 PMCID: PMC5874882 DOI: 10.3390/bioengineering5010016] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2017] [Revised: 02/04/2018] [Accepted: 02/07/2018] [Indexed: 12/02/2022] Open
Abstract
The aim of the present study was to make a fenofibrate (FNB) nanocrystal (NC) by wet media milling, characterizations and formulates into oral strip-films (OSFs). Mechanical properties, redispersion study, and solid-state characterizations results suggested that reduction of drug crystal size at nanoscale and incorporation into OSFs does not affect the solid-state properties of the drug. In vitro dissolution kinetics showed enhanced dissolution rate was easily manipulated by changing the thickness of the OSF. In situ UV-imaging was used to monitor drug dissolution qualitatively and quantitatively in real time. Results confirm that the intrinsic dissolution rates and surface drug concentration measured with this device were in agreement with the USP-IV dissolution profiles. In vivo pharmacokinetics in rabbits showed a significant difference in the pharmacokinetics parameter (1.4 fold increase bioavailability) of FNB NC-loaded OSFs as compared to the marketed formulation “Tricor” and as-received (pristine) drug. This approach of drug nanocrystallization and incorporation into OSFs may have significant applications in cost-effective tools for bioavailability enhancement of FNB.
Collapse
Affiliation(s)
- Bhavesh D Kevadiya
- Department of Chemical, Biological and Pharmaceutical Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA.
| | - Manish Barvaliya
- Department of Pharmacology, Government Medical College, Bhavnagar 364002, Gujarat, India.
| | - Lu Zhang
- Department of Chemical, Biological and Pharmaceutical Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA.
| | - Ashish Anovadiya
- Department of Pharmacology, Government Medical College, Bhavnagar 364002, Gujarat, India.
| | - Harshad Brahmbhatt
- Analytical Discipline and Centralized Instrument Facility, The Academy of Scientific & Innovative Research (AcSIR), Central Salt and Marine Chemicals Research Institute, Council of Scientific and Industrial Research (CSIR), G.B. Marg, Bhavnagar 364002, Gujarat, India.
| | - Parimal Paul
- Analytical Discipline and Centralized Instrument Facility, The Academy of Scientific & Innovative Research (AcSIR), Central Salt and Marine Chemicals Research Institute, Council of Scientific and Industrial Research (CSIR), G.B. Marg, Bhavnagar 364002, Gujarat, India.
| | - Chandrabhanu Tripathi
- Department of Pharmacology, Government Medical College, Bhavnagar 364002, Gujarat, India.
| |
Collapse
|
10
|
Zhang Y, Chen X, Zhao B, Wu H, Yuan L, Zhang H, Dai W, He B, Xing G, Zhang Q, Wang X. Biosafety study and mechanism comparison on two types of silica with different nanostructures. Toxicol Res (Camb) 2017; 6:487-498. [PMID: 30090517 PMCID: PMC6062300 DOI: 10.1039/c7tx00076f] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2017] [Accepted: 04/21/2017] [Indexed: 11/21/2022] Open
Abstract
Silica is frequently used in oral drug delivery; however, its biosafety, particularly concerned with its nanostructure, has not been comprehensively studied yet. Here, the in vitro and in vivo biosafety of two types of silica (A200, nano-sized or micron-sized agglomerates; S350, micro-sized particles with nanopores) were compared and the possible reasons for the differences were explored. The results indicated that both A200 and S350 could inhibit the growth of Caco-2 cells by inducing apoptosis and changing the cell cycle progression. A200 showed a stronger influence than S350 in most of the in vitro experiments. In the in vivo study in KM mice, both A200 and S350 could change the blood constituents under the tested conditions; A200 also increased the levels of inflammatory factors in plasma and the numbers of CD4+ lymphocyte subsets. No obvious organic damage was observed in either the A200-treated or S350-treated groups. The transport study showed that neither A200 nor S350 were readily transported across the intestinal epithelial barrier in vitro and in vivo, but A200 could transport across the lymphatic-associated epithelium and accumulate in the Peyer's Patches, which might explain the A200-induced immune response. The increased transport of A200 might relate to its particle size, dispersion state and specific surface area. In conclusion, these results demonstrated that A200 and S350 exhibited diverse biosafety aspects, which correlated with their different nanostructures. We believe this study will provide some scientific information about the biosafety of A200 and S350 for their applications in oral drug delivery systems.
Collapse
Affiliation(s)
- Yang Zhang
- Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems , School of Pharmaceutical Sciences , Peking University , Beijing 100191 , China . ; Tel: +86-10-82805935
| | - Xianhui Chen
- Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems , School of Pharmaceutical Sciences , Peking University , Beijing 100191 , China . ; Tel: +86-10-82805935
| | - Bo Zhao
- Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems , School of Pharmaceutical Sciences , Peking University , Beijing 100191 , China . ; Tel: +86-10-82805935
| | - Hounan Wu
- Medical and Healthy Analytical Center , Peking University , Beijing 100191 , China
| | - Lan Yuan
- Medical and Healthy Analytical Center , Peking University , Beijing 100191 , China
| | - Hua Zhang
- Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems , School of Pharmaceutical Sciences , Peking University , Beijing 100191 , China . ; Tel: +86-10-82805935
| | - Wenbing Dai
- Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems , School of Pharmaceutical Sciences , Peking University , Beijing 100191 , China . ; Tel: +86-10-82805935
| | - Bing He
- Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems , School of Pharmaceutical Sciences , Peking University , Beijing 100191 , China . ; Tel: +86-10-82805935
| | - Gengmei Xing
- CAS Key Laboratory for Biomedical Effects of Nanomaterial & Nanosafety , Institute of High Energy Physics , Chinese Academy of Science (CAS) , Beijing 100049 , China
| | - Qiang Zhang
- Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems , School of Pharmaceutical Sciences , Peking University , Beijing 100191 , China . ; Tel: +86-10-82805935
- State Key Laboratory of Natural and Biomimetic Drugs , Peking University , Beijing 100191 , China
| | - Xueqing Wang
- Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems , School of Pharmaceutical Sciences , Peking University , Beijing 100191 , China . ; Tel: +86-10-82805935
| |
Collapse
|
11
|
O'Shea JP, Nagarsekar K, Wieber A, Witt V, Herbert E, O'Driscoll CM, Saal C, Lubda D, Griffin BT, Dressman JB. Mesoporous silica-based dosage forms improve bioavailability of poorly soluble drugs in pigs: case example fenofibrate. J Pharm Pharmacol 2017. [DOI: 10.1111/jphp.12767] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Abstract
Objectives
Mesoporous silicas (SLC) have demonstrated considerable potential to improve bioavailability of poorly soluble drugs by facilitating rapid dissolution and generating supersaturation. The addition of certain polymers can further enhance the dissolution of these formulations by preventing drug precipitation. This study uses fenofibrate as a model drug to investigate the performance of an SLC-based formulation, delivered with hydroxypropyl methylcellulose acetate succinate (HPMCAS) as a precipitation inhibitor, in pigs. The ability of biorelevant dissolution testing to predict the in vivo performance was also assessed.
Key findings
Fenofibrate-loaded mesoporous silica (FF-SLC), together with HPMCAS, displayed significant improvements in biorelevant dissolution tests relative to a reference formulation consisting of a physical mixture of crystalline fenofibrate with HPMCAS. In vivo assessment in fasted pigs demonstrated bioavailabilities of 86.69 ± 35.37% with combination of FF-SLC and HPMCAS in capsule form and 75.47 ± 14.58% as a suspension, compared to 19.92 ± 9.89% with the reference formulation. A positive correlation was identified between bioavailability and dissolution efficiency.
Conclusions
The substantial improvements in bioavailability of fenofibrate from the SLC-based formulations confirm the ability of this formulation strategy to overcome the dissolution and solubility limitations, further raising the prospects of a future commercially available SLC-based formulation.
Collapse
Affiliation(s)
- Joseph P O'Shea
- Pharmacodelivery Group, School of Pharmacy, University College Cork, Cork, Ireland
| | - Kalpa Nagarsekar
- Institute of Pharmaceutical Technology, Goethe University, Frankfurt am Main, Germany
| | - Alena Wieber
- Actives & Formulation Research and Development, MilliporeSigma, a Business of Merck KGaA, Darmstadt, Germany
| | - Vanessa Witt
- Actives & Formulation Research and Development, MilliporeSigma, a Business of Merck KGaA, Darmstadt, Germany
| | - Elisabeth Herbert
- Institute of Pharmaceutical Technology, Goethe University, Frankfurt am Main, Germany
| | | | | | - Dieter Lubda
- Actives & Formulation Research and Development, MilliporeSigma, a Business of Merck KGaA, Darmstadt, Germany
| | - Brendan T Griffin
- Pharmacodelivery Group, School of Pharmacy, University College Cork, Cork, Ireland
| | - Jennifer B Dressman
- Institute of Pharmaceutical Technology, Goethe University, Frankfurt am Main, Germany
| |
Collapse
|
12
|
Guo Y, Zhong T, Duan XC, Zhang S, Yao X, Yin YF, Huang D, Ren W, Zhang Q, Zhang X. Improving anti-tumor activity of sorafenib tosylate by lipid- and polymer-coated nanomatrix. Drug Deliv 2017; 24:270-277. [PMID: 28165798 PMCID: PMC8241045 DOI: 10.1080/10717544.2016.1245371] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
In the present study, we select the Sylysia 350 (Sylysia) as mesoporous material, distearoylphosphatidylethanolamine-poly(ethylene glycol)2000 (DSPE-PEG) as absorption enhancer and hydroxy propyl methyl cellulose (HPMC) as crystallization inhibitor to prepare sorafenib tosylate (SFN) nanomitrix (MSNM@SFN) for improving the anti-tumor activity of SFN. The MSNM@SFN was prepared by solvent evaporation method. The solubility, dissolution, and bioavailability of SFN in MSNM@SFN were also investigated. The anti-tumor activity of MSNM@SFN was evaluated in vitro and in vivo. Our results indicated that the solubility and dissolution of SFN in MSNM@SFN were significantly increased. The oral bioavailability of SFN in MSNM@SFN was greatly improved 7.7-fold compared with that in SFN suspension. The enhanced anti-tumor activity of MSNM@SFN was confirmed in vitro and in vivo experiments. This nanomatrix developed in this study could be a promising drug delivery platform for improving the therapeutic efficacy of poorly water-soluble drugs.
Collapse
Affiliation(s)
- Yang Guo
- a Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University , Beijing , China.,b Department of Pharmaceutics , School of Pharmaceutical Sciences, Peking University , Beijing , China , and
| | - Ting Zhong
- a Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University , Beijing , China.,b Department of Pharmaceutics , School of Pharmaceutical Sciences, Peking University , Beijing , China , and
| | - Xiao-Chuan Duan
- a Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University , Beijing , China.,b Department of Pharmaceutics , School of Pharmaceutical Sciences, Peking University , Beijing , China , and
| | - Shuang Zhang
- a Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University , Beijing , China.,b Department of Pharmaceutics , School of Pharmaceutical Sciences, Peking University , Beijing , China , and
| | - Xin Yao
- a Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University , Beijing , China.,b Department of Pharmaceutics , School of Pharmaceutical Sciences, Peking University , Beijing , China , and
| | - Yi-Fan Yin
- a Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University , Beijing , China.,b Department of Pharmaceutics , School of Pharmaceutical Sciences, Peking University , Beijing , China , and
| | - Dan Huang
- a Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University , Beijing , China.,b Department of Pharmaceutics , School of Pharmaceutical Sciences, Peking University , Beijing , China , and
| | - Wei Ren
- a Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University , Beijing , China.,b Department of Pharmaceutics , School of Pharmaceutical Sciences, Peking University , Beijing , China , and
| | - Qiang Zhang
- a Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University , Beijing , China.,b Department of Pharmaceutics , School of Pharmaceutical Sciences, Peking University , Beijing , China , and.,c State Key Laboratory of Natural and Biomimetic Drugs, Peking University , Beijing , China
| | - Xuan Zhang
- a Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University , Beijing , China.,b Department of Pharmaceutics , School of Pharmaceutical Sciences, Peking University , Beijing , China , and
| |
Collapse
|
13
|
Oral hesperidin—Amorphization and improved dissolution properties by controlled loading onto porous silica. Int J Pharm 2017; 518:253-263. [DOI: 10.1016/j.ijpharm.2016.11.005] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2016] [Revised: 10/26/2016] [Accepted: 11/02/2016] [Indexed: 11/19/2022]
|
14
|
Wei Q, Keck CM, Müller RH. Preparation and tableting of long-term stable amorphous rutin using porous silica. Eur J Pharm Biopharm 2016; 113:97-107. [PMID: 27847275 DOI: 10.1016/j.ejpb.2016.11.009] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2016] [Revised: 10/27/2016] [Accepted: 11/03/2016] [Indexed: 11/16/2022]
Abstract
Amorphous state of drugs increases the oral bioavailability, but typically faces physical stability problems. Amorphous rutin was generated and physically stabilized by encapsulating inside mesopores of porous AEROPERL® 300 Pharma and named as rutin CapsMorph® in this study. AEROPERL® 300 Pharma was loaded with rutin dissolved in DMSO containing Tween 80, and subsequently the solvent evaporated (wetness impregnation method). The loading process was monitored by light microscopy and scanning electron microscopy (SEM). X-ray diffraction (XRD) and differential scanning calorimetry (DSC) were used to confirm the amorphous state in AEROPERL® 300 Pharma. A loading of 20% of the rutin-AEROPERL® 300 Pharma mixture was obtained. The amorphous state proved to be stable over 2years of storage at room temperature. Due to the amorphous state and the nanosize of the rutin in the mesopores, the kinetic saturation solubility increased to about 4mg/ml (water, 0.1MHCl, pH 6.8PBS) compared to the maximum observed thermodynamic equilibrium solubility of rutin raw drug powder of only 74.48±1.42μg/ml in pH 6.8PBS (=increase by factor about 54). The dissolution velocity also increased distinctly, e.g. about 96.1% of rutin dissolution from CapsMorph® powder in water within 5min compared to less than 40% of raw drug powder after 3h. Tablets were produced with rutin CapsMorph®, raw drug powder and their dissolution velocity compared to a marketed product. About 83.0-95.6% were released from the rutin CapsMorph® tablet within 5min, compared to 42.7-52.5% from the marketed tablet after 3h (water, 0.1MHCl, pH 6.8PBS). After dissolution the supersaturation level of rutin CapsMorph® remained over about 2h, then solubility slowly reduced, but remained after 48h still multifold above the thermodynamic rutin solubility. This should be sufficient for many poorly soluble drugs to achieve a sufficient bioavailability. For optimal exploitation of the supersaturation, a multiple step release system could be used, e.g. release of CapsMorph® particles every 2-3h.
Collapse
Affiliation(s)
- Qionghua Wei
- Institute of Pharmacy, Department of Pharmaceutics, Biopharmaceutics & NutriCosmetics, Freie Universität Berlin, Kelchstr. 31, 12169 Berlin, Germany
| | | | - Rainer H Müller
- Institute of Pharmacy, Department of Pharmaceutics, Biopharmaceutics & NutriCosmetics, Freie Universität Berlin, Kelchstr. 31, 12169 Berlin, Germany.
| |
Collapse
|
15
|
Lainé AL, Price D, Davis J, Roberts D, Hudson R, Back K, Bungay P, Flanagan N. Enhanced oral delivery of celecoxib via the development of a supersaturable amorphous formulation utilising mesoporous silica and co-loaded HPMCAS. Int J Pharm 2016; 512:118-125. [DOI: 10.1016/j.ijpharm.2016.08.034] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2016] [Revised: 08/10/2016] [Accepted: 08/15/2016] [Indexed: 11/15/2022]
|
16
|
Evaluation of Three Amorphous Drug Delivery Technologies to Improve the Oral Absorption of Flubendazole. J Pharm Sci 2016; 105:2782-2793. [PMID: 27113473 PMCID: PMC4988473 DOI: 10.1016/j.xphs.2016.03.003] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2015] [Revised: 03/02/2016] [Accepted: 03/03/2016] [Indexed: 11/24/2022]
Abstract
This study investigates 3 amorphous technologies to improve the dissolution rate and oral bioavailability of flubendazole (FLU). The selected approaches are (1) a standard spray-dried dispersion with hydroxypropylmethylcellulose (HPMC) E5 or polyvinylpyrrolidone-vinyl acetate 64, both with Vitamin E d-α-tocopheryl polyethylene glycol succinate; (2) a modified process spray-dried dispersion (MPSDD) with either HPMC E3 or hydroxypropylmethylcellulose acetate succinate (HPMCAS-M); and (3) confining FLU in ordered mesoporous silica (OMS). The physicochemical stability and in vitro release of optimized formulations were evaluated following 2 weeks of open conditions at 25°C/60% relative humidity (RH) and 40°C/75% RH. All formulations remained amorphous at 25°C/60% RH. Only the MPSDD formulation containing HPMCAS-M and 3/7 (wt./wt.) FLU/OMS did not crystallize following 40°C/75% RH exposure. The OMS and MPSDD formulations contained the lowest and highest amount of hydrolyzed degradant, respectively. All formulations were dosed to rats at 20 mg/kg in suspension. One FLU/OMS formulation was also dosed as a capsule blend. Plasma concentration profiles were determined following a single dose. In vivo findings show that the OMS capsule and suspension resulted in the overall highest area under the curve and Cmax values, respectively. These results cross-evaluate various amorphous formulations and provide a link to enhanced biopharmaceutical performance.
Collapse
|
17
|
Chen T, Yang J, Chen L, Qian X, Zheng Q, Fu T, Qiao H, Li J, Di L. Use of ordered mesoporous silica-loaded phyto-phospholipid complex for BCS IV class plant drug to enhance oral bioavailability: a case report of tanshinone IIA. RSC Adv 2016. [DOI: 10.1039/c6ra22778c] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
A CDDS was composed of PC and SD, using TS as a model drug. The marked improvements in oral bioavailability by TSPC-SD may result from comprehensive effects, including improved lg Po/wandPappviaPC, and increased dissolution rates from SD.
Collapse
Affiliation(s)
- Ting Chen
- School of Pharmacy
- Nanjing University of Chinese Medicine
- Nanjing 210023
- PR China
- Jiangsu Provincial TCM Engineering Technology Research Center of High Efficient Drug Delivery System (DDS)
| | - Junhui Yang
- Jiangyin Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Chinese Medicine
- Jiangyin 214400
- PR China
| | - Lihua Chen
- School of Pharmacy
- Jiangxi University of Traditional Chinese Medicine
- Nanchang 330004
- PR China
| | - Xiaocui Qian
- School of Pharmacy
- Nanjing University of Chinese Medicine
- Nanjing 210023
- PR China
- Jiangsu Provincial TCM Engineering Technology Research Center of High Efficient Drug Delivery System (DDS)
| | - Qin Zheng
- School of Pharmacy
- Jiangxi University of Traditional Chinese Medicine
- Nanchang 330004
- PR China
| | - Tingming Fu
- School of Pharmacy
- Nanjing University of Chinese Medicine
- Nanjing 210023
- PR China
- Jiangsu Provincial TCM Engineering Technology Research Center of High Efficient Drug Delivery System (DDS)
| | - Hongzhi Qiao
- School of Pharmacy
- Nanjing University of Chinese Medicine
- Nanjing 210023
- PR China
- Jiangsu Provincial TCM Engineering Technology Research Center of High Efficient Drug Delivery System (DDS)
| | - Junsong Li
- School of Pharmacy
- Nanjing University of Chinese Medicine
- Nanjing 210023
- PR China
- Jiangsu Provincial TCM Engineering Technology Research Center of High Efficient Drug Delivery System (DDS)
| | - Liuqing Di
- School of Pharmacy
- Nanjing University of Chinese Medicine
- Nanjing 210023
- PR China
- Jiangsu Provincial TCM Engineering Technology Research Center of High Efficient Drug Delivery System (DDS)
| |
Collapse
|
18
|
McCarthy CA, Ahern RJ, Dontireddy R, Ryan KB, Crean AM. Mesoporous silica formulation strategies for drug dissolution enhancement: a review. Expert Opin Drug Deliv 2015; 13:93-108. [DOI: 10.1517/17425247.2016.1100165] [Citation(s) in RCA: 106] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
19
|
Meeus J, Scurr DJ, Amssoms K, Wuyts K, Annaert P, Davies MC, Roberts CJ, Van den Mooter G. In vivo evaluation of different formulation strategies for sustained release injectables of a poorly soluble HIV protease inhibitor. J Control Release 2014; 199:1-9. [PMID: 25485732 DOI: 10.1016/j.jconrel.2014.11.020] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2014] [Revised: 11/15/2014] [Accepted: 11/18/2014] [Indexed: 11/24/2022]
Abstract
At present no scientific rationale exists for selecting a particular enabling strategy to formulate a poorly water-soluble drug, although this is crucial as it will influence the in vivo performance of the resulting formulation. This study provides an insight into this complicated decision making process for a poorly soluble human immunodeficiency virus (HIV) protease inhibitor based upon in vivo test results. A formulation strategy based on the molecular dispersion of this active pharmaceutical ingredient (API) into a biphasic matrix consisting of water-insoluble poly(lactic-co-glycolic acid) (PLGA) and water-soluble polyvinylpyrrolidone (PVP) was evaluated. The long-term in vivo performance of this strategy was compared to that of other solubility enhancing approaches by evaluating exposure of the API in male Beagle dogs. Solid dispersions, based on a PLGA/PVP matrix, were compared to solid dispersions in a pure PLGA matrix. Additionally these solid dispersion strategies were compared to the strategy of particle size reduction by means of an API microsuspension. The in vivo performance of the various formulations over a period of 28days after intramuscular injection was evaluated by the observed initial burst release, plasma concentration-time profiles, time at which maximum plasma levels were reached and the estimated bioavailability. Compared to the other formulation strategies assessed, it was concluded that the addition of PVP in a PLGA matrix resulted in vivo in a more sustained release as well as a higher amount of drug released from the polymeric matrix. This was explained based on the structure of these binary PLGA/PVP matrices where the pore network originating from rapidly dissolving PVP plays a key role. Moreover, the results suggest that the API release from this type of formulation could be delayed by increasing the amount of PLGA in the formulation.
Collapse
Affiliation(s)
- Joke Meeus
- Drug Delivery and Disposition, KU Leuven, Herestraat 49, Leuven, Belgium
| | - David J Scurr
- Laboratory of Biophysics and Surface Analysis, School of Pharmacy, The University of Nottingham, University Park, Boots Science Building, Nottingham, United Kingdom
| | - Katie Amssoms
- Pharmaceutical Companies of Johnson & Johnson, Janssen, Discovery Sciences, PD&S_PDM, Turnhoutseweg 30, Beerse, Belgium
| | - Koen Wuyts
- Pharmaceutical Companies of Johnson & Johnson, Janssen, Discovery Sciences, PD&S_PDM, Turnhoutseweg 30, Beerse, Belgium
| | - Pieter Annaert
- Drug Delivery and Disposition, KU Leuven, Herestraat 49, Leuven, Belgium
| | - Martyn C Davies
- Laboratory of Biophysics and Surface Analysis, School of Pharmacy, The University of Nottingham, University Park, Boots Science Building, Nottingham, United Kingdom
| | - Clive J Roberts
- Laboratory of Biophysics and Surface Analysis, School of Pharmacy, The University of Nottingham, University Park, Boots Science Building, Nottingham, United Kingdom
| | - Guy Van den Mooter
- Drug Delivery and Disposition, KU Leuven, Herestraat 49, Leuven, Belgium.
| |
Collapse
|
20
|
Physical stabilization of low-molecular-weight amorphous drugs in the solid state: a material science approach. Ther Deliv 2014; 5:817-41. [DOI: 10.4155/tde.14.39] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
Use of the amorphous state is considered to be one of the most effective approaches for improving the dissolution and subsequent oral bioavailability of poorly water-soluble drugs. However as the amorphous state has much higher physical instability in comparison with its crystalline counterpart, stabilization of amorphous drugs in a solid-dosage form presents a major challenge to formulators. The currently used approaches for stabilizing amorphous drug are discussed in this article with respect to their preparation, mechanism of stabilization and limitations. In order to realize the potential of amorphous formulations, significant efforts are required to enable the prediction of formulation performance. This will facilitate the development of computational tools that can inform a rapid and rational formulation development process for amorphous drugs.
Collapse
|
21
|
Vialpando M, Albertini B, Passerini N, Heyden YV, Rombaut P, Martens JA, Mooter GVD. Agglomeration of Mesoporous Silica by Melt and Steam Granulation. Part II: Screening of Steam Granulation Process Variables Using a Factorial Design. J Pharm Sci 2013; 102:3978-86. [DOI: 10.1002/jps.23699] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2013] [Revised: 07/22/2013] [Accepted: 07/24/2013] [Indexed: 11/06/2022]
|
22
|
Vialpando M, Albertini B, Passerini N, Bergers D, Rombaut P, Martens JA, Van Den Mooter G. Agglomeration of Mesoporous Silica by Melt and Steam Granulation. Part I: A Comparison Between Disordered and Ordered Mesoporous Silica. J Pharm Sci 2013; 102:3966-77. [DOI: 10.1002/jps.23700] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2013] [Revised: 07/22/2013] [Accepted: 07/24/2013] [Indexed: 02/03/2023]
|
23
|
Mellaerts R, Fayad EJ, Van den Mooter G, Augustijns P, Rivallan M, Thibault-Starzyk F, Martens JA. In Situ FT-IR Investigation of Etravirine Speciation in Pores of SBA-15 Ordered Mesoporous Silica Material upon Contact with Water. Mol Pharm 2013; 10:567-73. [DOI: 10.1021/mp300229q] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Affiliation(s)
- Randy Mellaerts
- Centre for Surface Chemistry
and Catalysis, Kasteelpark Arenberg 23, Katholieke Universiteit Leuven, BE-3001 Heverlee, Belgium
| | - Elie J. Fayad
- Laboratoire Catalyse et Spectrochimie,
ENSICAEN, Université de Caen Basse-Normandie, CNRS, Boulevard Maréchal Juin 6, 14050 Caen, France
| | - Guy Van den Mooter
- Laboratory for Pharmacotechnology and Biopharmacy, O&N2, Herestraat 49-box 921, Katholieke Universiteit Leuven, BE-3000 Leuven, Belgium
| | - Patrick Augustijns
- Laboratory for Pharmacotechnology and Biopharmacy, O&N2, Herestraat 49-box 921, Katholieke Universiteit Leuven, BE-3000 Leuven, Belgium
| | - Mickaël Rivallan
- Laboratoire Catalyse et Spectrochimie,
ENSICAEN, Université de Caen Basse-Normandie, CNRS, Boulevard Maréchal Juin 6, 14050 Caen, France
| | - Frédéric Thibault-Starzyk
- Laboratoire Catalyse et Spectrochimie,
ENSICAEN, Université de Caen Basse-Normandie, CNRS, Boulevard Maréchal Juin 6, 14050 Caen, France
| | - Johan A. Martens
- Centre for Surface Chemistry
and Catalysis, Kasteelpark Arenberg 23, Katholieke Universiteit Leuven, BE-3001 Heverlee, Belgium
| |
Collapse
|
24
|
Development of mesoporous silica nanomaterials as a vehicle for anticancer drug delivery. Ther Deliv 2012; 3:389-404. [PMID: 22506096 DOI: 10.4155/tde.12.9] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
The development of delivery vehicles that would carry therapeutic agents selectively to cancer cells has become an important focus in biomedical research. Nanoparticles have received much attention because the advances made in this field have resulted in multiple biocompatible materials. In particular, mesoporous silica nanoparticles (MSNs) offer a solid framework with porous structure and high surface area that allows for the attachment of different functional groups. In this article we discuss the different surface modifications made to MSNs that have allowed for the construction of targeted nanoparticles to enhance accumulation and uptake in target sites, the incorporation of nanomachines for controlled cargo release and the combination with superparamagnetic metals for MRI cell labeling. We also discuss biocompatibility, biodistribution and drug-delivery efficacy of MSNs. Finally, we mention the construction of multifunctional nanoparticles that combine all of the previously examined nanoparticle modifications.
Collapse
|
25
|
Vialpando M, Backhuijs F, Martens JA, Van den Mooter G. Risk assessment of premature drug release during wet granulation of ordered mesoporous silica loaded with poorly soluble compounds itraconazole, fenofibrate, naproxen, and ibuprofen. Eur J Pharm Biopharm 2012; 81:190-8. [DOI: 10.1016/j.ejpb.2012.01.012] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2011] [Revised: 01/17/2012] [Accepted: 01/19/2012] [Indexed: 11/30/2022]
|